GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Ludwig Enterprises Inc (OTCPK:LUDG) » Definitions » Loans Receivable

Ludwig Enterprises (Ludwig Enterprises) Loans Receivable : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Ludwig Enterprises Loans Receivable?

Ludwig Enterprises's Loans Receivable for the quarter that ended in Mar. 2024 was $0.00 Mil.


Ludwig Enterprises Loans Receivable Historical Data

The historical data trend for Ludwig Enterprises's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ludwig Enterprises Loans Receivable Chart

Ludwig Enterprises Annual Data
Trend Dec22 Dec23
Loans Receivable
- -

Ludwig Enterprises Quarterly Data
Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Loans Receivable Get a 7-Day Free Trial - - - - -

Ludwig Enterprises Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Ludwig Enterprises Loans Receivable Related Terms

Thank you for viewing the detailed overview of Ludwig Enterprises's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Ludwig Enterprises (Ludwig Enterprises) Business Description

Traded in Other Exchanges
N/A
Address
1749 VICTORIAN AVENUE, Suite C-350, Sparks, NV, USA, 89431
Ludwig Enterprises Inc is a publicly traded Medical Technology Holding Company with Precision Genomics, Inc. and MyRNA for Life, Inc. as wholly owned subsidiaries. The company's advancements in medical technology and Artificial Intelligence (AI) have awarded it with cutting-edge genomic tools. These genomic tools have the potential to detect diseases early but also to customize treatments that may improve patient outcomes and, in some cases, even extend life. Ludwig is at the forefront of this new era with their proprietary mRNA genetic technology that has the potential to detect genetic biomarkers for inflammatory-driven diseases, including but not limited to heart disease, diabetes, preeclampsia, and cancer. It manages its business on the basis of one operating and reportable segment.